Primary immunodeficiencies (PIDs) are rare monogenic inborn errors of immunity that result in impairment of functions of the human immune system. PIDs have a broad phenotype with increased morbidity and mortality, and treatment choices are often complex. With increased accessibility of next-generation sequencing (NGS), the rate of discovery of genetic causes for PID has increased exponentially. Identification of an underlying monogenic diagnosis provides important clinical benefits for patients with the potential to alter treatments, facilitate genetic counselling, and pre-implantation diagnostics. We investigated a NGS PID panel of 242 genes within clinical care across a range of PID phenotypes. We also evaluated Phenomizer to predict causal genes from human phenotype ontology (HPO) terms. Twenty-seven participants were recruited, and a total of 15 reportable variants were identified in 48% (13/27) of the participants. The panel results had implications for treatment in 37% (10/27) of participants. Phenomizer identified the genes harbouring variants from HPO terms in 33% (9/27) of participants. This study shows the clinical efficacy that genetic testing has in the care of PID. However, it also highlights some of the disadvantages of gene panels in the rapidly moving field of PID genomics and current challenges in HPO term assignment for PID.
| INTRODUCTION
Primary immunodeficiency (PIDs) are inborn errors of immunity that encompass a collection of rare monogenic diseases resulting in impairment of 1 or more functions of the human immune system. PID has a broad phenotype including severe susceptibility to infections, allergy, autoimmunity/inflammation, and malignancy. 1 These disease manifestations cause increased morbidity and mortality in patients, and treatment choices are often complex. With the increased accessibility of next-generation sequencing (NGS), the rate of discovery of genetic causes for PID has increased exponentially in recent years, with now over 300 monogenic causes for PID described. 2, 3 The increasing number of monogenic causes identified for PID, coupled with knowledge of how these genetic alterations impact on protein and cellular functions, has led to the introduction of precision medical interventions targeting specific defects in patients. 4, 5 Traditional treatments for PID consist of prophylaxis against infection, with antimicrobials and immunoglobulin, iatrogenic immunomodulation with high inherent risk associated with additional untargeted immunosuppression, and bone marrow transplantation in severe cases. Precision therapies now include targeted immunosuppression in cases of autoimmune/inflammatory manifestations and gene therapy to correct germline errors in autologous haematopoietic stem cells. 6, 7 These therapeutic approaches have the potential to dramatically improve the prognoses for patients with PID. [7] [8] [9] Precision treatments, as well with genetic family counselling and preimplantation diagnostics, are only possible with knowledge of the causal monogenic variant in patients, and recent progressions in diagnostics and treatments underline the importance of genomic investigations in the clinical care of patients with PID. 10, 11 Current genomic methodologies used for the investigation vary from Sanger sequencing of single candidate genes, to NGS gene panels, whole exome sequencing (WES) and now whole genome sequencing (WGS). [12] [13] [14] The most widely used technique within routine clinical care remains NGS gene panels due to economic, data handling, and the result turnaround time advantages. 15 NGS gene panels can provide a comprehensive method for diagnostics in PID, with reported diagnostic rates between 15% and 70%, depending on the PID population and phenotypic criteria of patients assessed. [16] [17] [18] [19] Due to the importance that a genetic diagnosis can have in the clinical management of PID, we investigated the diagnostic utility of an NGS panel of 242 PID genes in clinical practice. To reflect patients encountered within routine clinics, we recruited and collected phenotypic data from a heterogeneous range of PID participants using human phenotype ontology (HPO) terms. 1, 20 We also assessed the ability of Phenomizer to construct candidate gene lists from participant HPO terms. 21 2 | MATERIALS AND METHODS 
| Participants

| Clinical phenotyping
Clinical phenotyping was performed from analysis of patient medical records and laboratory results. Phenotypic data were recorded in HPO terms (Table S1 , Supporting Information). 
| DNA preparation
| Bioinformatic analysis
Per-cycle BCL basecall files were converted into demultiplexed perread FASTQ files using bcl2fastq software (Illumina, California).
Resulting FASTQ files were quality checked and processed according to GATK best practice guidelines and aligned to the GRCh37/hg19 reference genome using BWA-MEM. Aggregation Consortium (ExAC). 23 Variants were then interrogated using in silico predictive tools PolyPhen2, 24 SIFT, 25 and Ensembl variant effector predictor (VEP). 26 BAM file read alignments were visually inspected for each variant identified using Integrative Genomics
Viewer (IGV). 27 Variants were subsequently graded according to the (Table S4 ) using a cut-off of P < .05 for gene likelihood probabilities as calculated by
Monte-Carlo random sampling with Bonferroni correction (a method known as Ontology Similarity Search with P values). 21 3 | RESULTS
| Clinical phenotypes
All 27 participants had a range of phenotypes compatible with PID. 1 The number of HPO terms assigned to participants ranged from minimum of 2 to maximum of 13 (median = 6) ( Figure 1 and Table S1 ).
| 242 PID gene panel results
There was coverage of >1× read depth in 99.52%, >30× read depth in 96.19%, and >50× read depth in 87.57% of the targeted exonic sequence across the 242 genes in the PID virtual panel (Table S2 ).
The mean read depth over the reportable variants was 98 reads (Table 1 ). Sixty seven known PID genes are not covered by TruSight
One Sequencing Panel and not included in the 242 PID gene panel (Table S3 ). P1 underwent an array comparative genomic hydridisation (aCGH) which identified a large 2 Mb monoallelic deletion within the 6q15 region (90511889-92156885). This deletion contained the genes MDN1, BACH2, MAP3K7, CASP8AP2, and GJA10. Haploinsufficiency of the transcription factor BACH2 has recently been described to cause immunodeficiency with autoimmunity, which is a similar clinical phenotype to that of P1, making this the likely cause of the participant's PID. 41 Two participants (P7 and P26) had 2 reportable variants identified. We assessed whether these 2 gene variants were likely to contribute to a blended phenotype of 2 distinct phenotypes that overlap within the individuals, or potentially contributed in a digenic mechanism for disease. Using GeneMANIA, we mapped the physical interactions of protein products, biological pathways, and genetic interactions of the genes GATA2:NLRP3 and STAT1:TNFRSF13B which did not find evidence of interactions ( Figure 2 ).
| Phenomizer candidate gene list results
Phenomizer-derived candidate gene lists identified the genes with reportable variants in 33% (9/27) of participants found to have a monogenic diagnosis (P2, P3, P5, P7, P16, P17, P23, P26, P27). Phenomizer did not identify the gene containing the reportable variant in
Number of human phenotype ontology terms assigned across the cohort displayed as a bar graph. Hypogammaglobulinaemia was the most frequently encountered being present in 66% (18/27) participants.
There were a number of traits present only in single participants could not be generated for P9 and P11 due to none of the predicted genes returned by Phenomizer having a significance level of P < .05.
In those participants who remained undiagnosed (P1, P4, P6, P8, P9, P11, P12, P13, P14, P15, P18, P19, P21, P22), filtering of variants from the Phenomizer candidate gene lists did not identify any reportable variants (Table S4 ).
| Clinical management and treatment implications
The genetic information gained from the 242 PID gene panel had implications for clinical management and treatment in 37% (10/27) of the cohort (Table 2 ).
NFKB1 haploinsufficiency is described to cause a wide range of autoimmune/inflammatory diseases. 42, 51 Both P2 and P3 presented with autoimmune cytopaenias and although both currently in remission, knowledge of the underlying genetic cause has meant that their immunosuppression with mycophenolate mofetil (MMF) should not be withdrawn due to high risk of disease relapse. Patients with NFKB1 haploinsufficiency suffer with EBV reactivation and disease due to intrinsic natural killer cell defects. 52 From the clinical and immunological phenotypes of P2 and P3, we would not have expected this, but now with knowledge of the monogenic PID cause we will continually monitor EBV viral loads due to lymphoma risk. 43 In P16 and P20, pathogenic CTLA4 missense variants cause immunodeficiency with multi-system autoimmunity due to impaired regulatory T cell function. 45, 53 A precision therapy can be administered in these patients with CTLA4:Ig fusion protein (Abatacept) to target autoimmunity. 44, 45 Activated phosphoinositide 3-kinase delta syndrome due to GOF variants in PIK3CD can cause lymphoproliferation and autoimmunity disease which is a significant cause of increased mortality. 54 These disease manifestations respond to inhibition of the hyperfunctional PIK3δ-AKT-mTOR pathway in lymphocytes of patients with use of mTOR inhibition by sirolimus or with PIK3δ inhibitors, such as idelalisib. 33, 36 Heterozygous frameshift variants in IFNGR1 cause recurrent infection with low virulence non-tuberculous mycobacteria (NTM) due to expression of a non-functional cell surface receptor on patients' cells that acts as a "decoy receptor" for interferon-γ. 35 This inborn error against NTMs can be improved with use of exogenous interferon-γ to boost signalling through the residual receptors on effector cells.
35
STAT1 GOF variants cause predisposition to chronic fungal infections as well as autoimmunity. 37, 47 TNFRSF13B variants increase the risk of autoimmunity and granulomatous inflammation. 48 Knowledge of both these variants in P26 has improved pulmonary and autoimmune monitoring, allowing proactive rather than reactive medicine, and confidence in the need to continue iatrogenic immunosuppression in an immunodeficient individual. Precision medicine is available with the janus kinase inhibitor ruxolitinib for STAT1 GOF patients. 46 Biallelic pathogenic DOCK8 variants cause a combined immunodeficiency that carries a high rate of mortality in early life. 55 As such, knowledge of this variant prompts early referral for bone marrow transplantation which improves outcome. 49, 50 The participants in whom a monogenic diagnosis was not established are undergoing broader diagnostic investigation such as WES/WGS, and functional interpretation of additional variants identified.
| DISCUSSION
This study highlights several advantages and disadvantages of NGS gene panels for diagnostic use in PID. The panel covered a relatively large number of PID genes at high read depth allowing a high sensitivity to detect SNP variants. This is an advantage of gene panels, FIGURE 2 GeneMANIA maps showing the physical interaction (red), biological pathway (blue), and genetic (green) interactions of the 2 genes containing reportable variants from (A): P7; GATA2 and NLRP3 and (B): P26; STAT1 and TNFRSF13B. Neither GATA2 and NLRP3 or STAT1 and TNFRSF13B are directly connected by any biological pathway. These data suggest that these variants cause overlapping phenotypes of 2 discrete diseases, opposed to a digenic mechanism of disease through an additive genetic effect in vivo which have a smaller region of target DNA sequence than WES or WGS. In this study, a "virtual" PID gene panel was applied as a filter to the data generated from the Illumina TruSight One Sequencing Panel (which targets~12 Mb of exonic DNA across 4813 genes in total). This represents a cost-effective way of generating sequence data limited to clinically relevant genes. By batching samples, we were able to produce results for £180/sample with a turnaround time of 4-8 weeks. In order to achieve this turnaround time. close working of a multi-disciplinary team comprising immunologists, technologists, bioinformaticians and geneticists was required working within the pipeline, and evaluating candidate variants in either a face-to-face or virtual multidisciplinary meetings. The mean read depth over reported PID gene variants in this series was 98 reads, which is more than is typically found in WES or WGS studies. 56 Owing to the smaller region of target DNA sequenced, gene panels generate less data than WES/WGS and therefore are faster to analyse with far fewer variants to interpret than would be expected through an untargeted approach.
The risk of incidental/additional genetic findings can also be minimised using a rational, targeted approach to data analysis and interpretation. Together these factors represent a compelling argument for the use of gene panels (albeit as "virtual" panels applied to An inherent limitation of gene panels is lack of inclusion of recently described/novel genes. This 242 PID gene panel does not include 67 known PID genes described since its development (S3 Table) . Many of these missing genes have subsequently been
shown to be prevalent in cohorts of PID patients. 57 Another disadvantage is highlighted by the results of P1, in whom a monogenic diagnosis was not reached with the PID gene panel, but an aCGH identified a large structural variant including the BACH2 gene as the cause of the patient's condition. 41 Large structural variants are not detectable from NGS gene panels, and although bioinformatics software exists to investigate for structural variants in NGS WES data it remains challenging due to the PCR amplification of DNA during library preparation and need for read de-duplication. This is an advantage of WGS which does not involve PCR amplification of DNA and has contiguous paired-end reads across the genome allowing for the detection of larger structural variants from read depths and split paired-end reads. 58, 59 In participants P7 and P26, 2 variants were identified that have been reported to be monogenic causes of PID (Table 1) . Digenic mechanisms for inherited genetic diseases are well described, but have not been identified in the field of PID. 60 Two distinct monogenic causes for PID have been rarely reported in the same individual resulting in a blended phenotype of 2 underlying monogenic PIDs. 61 Results of large scale genomic investigation studies suggest that~5% of individuals with rare disease, initially considered to have a single monogenic cause for disease, will have a blended phenotype due to the presence of ≥2 penetrant monogenic variants. 31 Methods to determine whether in these cases the presence of these 2 reportable variants represent digenic inheritance models for a single disease entity (that would not manifest without both variants being present)
or a blended phenotype due to dual monogenic diagnoses overlapping within the same individual have been developed. 31 Results of our cases show that neither GATA2:NLRP3 or STAT1:TNFRSF13B reside in the same cellular biological pathways (Figure 2) , suggesting a blend of 2 monogenic disease phenotypes.
Review of these variants reveals that NLRP3 p.R490K, initially described as pathogenic causing a periodic fever syndrome, 39 is also reported to show reduced clinical penetrance in some individuals. 62 In P7, the clinical phenotype does contain traits that are supportive of an autoinflammatory syndrome with episodic fever and raised intracranial pressure (Table S4) In P26, we consider that these variants may have also resulted in an overlapping blended phenotype as there is no direct interaction or common pathway between STAT1 and TNFRSF13B ( Figure 2 The phenotyping of PID patients often requires detailed, bespoke, functional immunological assays to determine specific defects in cellular functions. 70 These data are difficult to accurately reflect in HPO terms which are often better suited to describe physical characteristics. Often the lack of a specific HPO term for a laboratory assay result (eg, impairment of specific T cell subset such as Th17 cells) means that a broader term such as "impaired T cell function" (HP:0005435) or "abnormality of interleukin secretion"
(HP:0011117) must be substituted. This use of broader HPO terms means that, via semantic relationships used by the Phenomizer algorithm, an excessive number of candidate genes are returned which may be missing the correct genetic diagnosis once a P < .05 to correct for random sampling is applied (Table S4) . Due to these current limitations in HPO terminology, a broad unbiased approach of interrogating all known PID genes appears to result in a better diagnostic yield than reliance on HPO-term-driven candidate gene lists. There appears a need to add additional HPO terms and data to improve these results for PID diagnostics in the future.
In conclusion, this study shows the clinical application and benefits that genetic testing has in the clinical care of PID. PID is particularly amenable to precision medicine, and accurate diagnostics readily translate into effective treatments. We show that this 242 PID gene panel can provide clinically important information for management of PID in the clinic. However, it also highlights some of the limitations and disadvantages of gene panels in the rapidly moving field of PID genomics and the current challenges in accurate HPO term assignment for PID phenotyping.
